Trump announces executive order to accelerate medical research and access to psychedelic drugs

Apr 18, 2026, 1:13:45 PM UTC(12 hours ago)

Impact: Medium

Affected Assets

The executive order directs the FDA and DEA to reduce regulatory red tape that has historically stymied research into Schedule I substances like psilocybin and ibogaine
A specific allocation of 50 million dollars is proposed for state-level research into ibogaine for treating opioid use disorder and post-traumatic stress disorder
The initiative follows a December order loosening federal restrictions on marijuana and CBD products as part of a broader push for alternative medical applications
Advocacy groups like Veterans Exploring Treatment Solutions and former Texas Governor Rick Perry have been instrumental in pushing for these reforms to help veterans
Market analysts expect the move to boost investment in biotech firms specializing in psychedelic-assisted therapies for treatment-resistant depression

TRUMP: ANNOUNCING HISTORIC REFORMS TO ACCELERATE ACCESS TO MEDICAL RESEARCH AND TREATMENT BASED ON PSYCHEDELIC DRUGS